HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On ‘Unclear Path’
The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares…
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $23
Morgan Stanley analyst Jeffrey Hung maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $22 to $23.
Morgan Stanley Maintains Equal-Weight on Zimmer Biomet Holdings, Lowers Price Target to $115
Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight and lowers the price target from $132 to $115.
Morgan Stanley Maintains Underweight on Watsco, Raises Price Target to $208
Morgan Stanley analyst Joshua Pokrzywinski maintains Watsco (NYSE:WSO) with a Underweight and raises the price target from $207 to $208.
Morgan Stanley Maintains Underweight on W.W. Grainger, Lowers Price Target to $421
Morgan Stanley analyst Joshua Pokrzywinski maintains W.W. Grainger (NYSE:GWW) with a Underweight and lowers the price target from $449 to $421.
Morgan Stanley Maintains Equal-Weight on Ventas, Lowers Price Target to $52
Morgan Stanley analyst Richard Hill maintains Ventas (NYSE:VTR) with a Equal-Weight and lowers the price target from $59 to $52.
Morgan Stanley Maintains Underweight on Urban Edge Props, Lowers Price Target to $14.25
Morgan Stanley analyst Richard Hill maintains Urban Edge Props (NYSE:UE) with a Underweight and lowers the price target from $16 to $14.25.
Morgan Stanley Maintains Underweight on Upstart Hldgs, Lowers Price Target to $15.5
Morgan Stanley analyst James Faucette maintains Upstart Hldgs (NASDAQ:UPST) with a Underweight and lowers the price target from $19 to $15.5.
BMO Capital Cuts Albertsons Price Target By 7%
BMO Capital analyst Kelly Bania lowered the price target on Albertsons Companies Inc (NYSE:ACI) to $24 from $26 and maintained an Underperform rating…